BRIDGE THE GAP WITH ORENITRAM
Orenitram provides clinical intervention for when intermediate-risk
patients with PAH need improvement of key measures of risk.1-3*
Assess risk, consider time, and leverage Orenitram for when your intermediate-risk patients need more.
Dosing With Patients in Mind
Discover dosing approaches and proactive adverse effect management to help confidently start a patient on Orenitram.
Considering the 90-Day Trial
Your patient may be eligible to start Orenitram at no cost for up to 90 days.
*2022 guidelines define measures of risk as 6MWD, FC, and NT-proBNP.4
To prescribe Orenitram for your patient, download and complete our Referral Form.Download Form
Ready to Get Started?
When intermediate-risk patients need clinical intervention, set them up for a successful start on Orenitram.1-3